[go: up one dir, main page]

WO2009025117A1 - Cdca1ペプチド及びこれを含む薬剤 - Google Patents

Cdca1ペプチド及びこれを含む薬剤 Download PDF

Info

Publication number
WO2009025117A1
WO2009025117A1 PCT/JP2008/060837 JP2008060837W WO2009025117A1 WO 2009025117 A1 WO2009025117 A1 WO 2009025117A1 JP 2008060837 W JP2008060837 W JP 2008060837W WO 2009025117 A1 WO2009025117 A1 WO 2009025117A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
same
pharmaceutical agent
seq
amino acid
Prior art date
Application number
PCT/JP2008/060837
Other languages
English (en)
French (fr)
Inventor
Yasuharu Nishimura
Michiko Harao
Takuya Tsunoda
Yusuke Nakamura
Original Assignee
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2008290061A priority Critical patent/AU2008290061B2/en
Priority to PL08777198T priority patent/PL2186889T3/pl
Priority to BRPI0815578A priority patent/BRPI0815578B8/pt
Priority to HK10107732.6A priority patent/HK1141312B/en
Priority to EP08777198.6A priority patent/EP2186889B1/en
Priority to RU2010110564/10A priority patent/RU2486195C2/ru
Priority to JP2009528970A priority patent/JP5493076B2/ja
Priority to MX2010002001A priority patent/MX2010002001A/es
Application filed by Oncotherapy Science, Inc. filed Critical Oncotherapy Science, Inc.
Priority to DK08777198.6T priority patent/DK2186889T3/en
Priority to US12/673,434 priority patent/US8598125B2/en
Priority to CA2696701A priority patent/CA2696701C/en
Priority to ES08777198.6T priority patent/ES2537323T3/es
Priority to CN2008801123961A priority patent/CN101835892B/zh
Publication of WO2009025117A1 publication Critical patent/WO2009025117A1/ja
Priority to IL203898A priority patent/IL203898A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本発明によれば、以下の（Ａ）又は（Ｂ）に記載のペプチドならびにその使用方法が提供される。 （Ａ）配列番号１又は２に記載のアミノ酸配列からなるペプチド。 （Ｂ）配列番号１又は２に記載のアミノ酸配列において、１個、２個または数個のアミノ酸が置換、欠失、挿入及び/又は付加されたアミノ酸配列からなり、キラーＴ細胞の誘導活性を示すペプチド。
PCT/JP2008/060837 2007-08-20 2008-06-13 Cdca1ペプチド及びこれを含む薬剤 WO2009025117A1 (ja)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2009528970A JP5493076B2 (ja) 2007-08-20 2008-06-13 Ｃｄｃａ１ペプチド及びこれを含む薬剤
BRPI0815578A BRPI0815578B8 (pt) 2007-08-20 2008-06-13 Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
HK10107732.6A HK1141312B (en) 2007-08-20 2008-06-13 Cdca1 peptide and pharmaceutical agent comprising the same
EP08777198.6A EP2186889B1 (en) 2007-08-20 2008-06-13 Cdca1 peptide and pharmaceutical agent comprising the same
RU2010110564/10A RU2486195C2 (ru) 2007-08-20 2008-06-13 Пептид cdca1 и включающее его фармацевтическое средство
MX2010002001A MX2010002001A (es) 2007-08-20 2008-06-13 Peptido cdca1 y agente farmaceutico que comprende elmismo.
DK08777198.6T DK2186889T3 (en) 2007-08-20 2008-06-13 CDCA1 PEPTID AND PHARMACEUTICAL COMPOSITION, INCLUDING THIS
AU2008290061A AU2008290061B2 (en) 2007-08-20 2008-06-13 CDCA1 peptide and pharmaceutical agent comprising the same
PL08777198T PL2186889T3 (pl) 2007-08-20 2008-06-13 Peptyd CDCA1 i środek farmaceutyczny go zawierający
US12/673,434 US8598125B2 (en) 2007-08-20 2008-06-13 CDCA1 peptide and pharmaceutical agent comprising the same
CA2696701A CA2696701C (en) 2007-08-20 2008-06-13 Cdca1 peptide and pharmaceutical agent comprising the same
ES08777198.6T ES2537323T3 (es) 2007-08-20 2008-06-13 Péptido CDCA1 y agente farmacéutico que lo comprende
CN2008801123961A CN101835892B (zh) 2007-08-20 2008-06-13 Cdca1肽和包含cdca1肽的药剂
IL203898A IL203898A (en) 2007-08-20 2010-02-11 Cdca1 protein, a pharmaceutical that contains it and uses it to treat cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007214000 2007-08-20
JP2007-214000 2007-08-20

Publications (1)

Publication Number Publication Date
WO2009025117A1 true WO2009025117A1 (ja) 2009-02-26

Family

ID=40378024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060837 WO2009025117A1 (ja) 2007-08-20 2008-06-13 Cdca1ペプチド及びこれを含む薬剤

Country Status (18)

Country Link
US (1) US8598125B2 (ja)
EP (1) EP2186889B1 (ja)
JP (1) JP5493076B2 (ja)
KR (1) KR101610353B1 (ja)
CN (1) CN101835892B (ja)
AU (1) AU2008290061B2 (ja)
BR (1) BRPI0815578B8 (ja)
CA (1) CA2696701C (ja)
DK (1) DK2186889T3 (ja)
ES (1) ES2537323T3 (ja)
IL (1) IL203898A (ja)
MX (1) MX2010002001A (ja)
PL (1) PL2186889T3 (ja)
PT (1) PT2186889E (ja)
RU (2) RU2486195C2 (ja)
SG (1) SG183698A1 (ja)
TW (1) TWI523660B (ja)
WO (1) WO2009025117A1 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153992A1 (en) * 2008-06-19 2009-12-23 Oncotherapy Science, Inc. Cdca1 epitope peptides and vaccines containing the same
US7943295B2 (en) 2005-07-29 2011-05-17 Oncotherapy Science, Inc. Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
US8569244B2 (en) 2007-08-20 2013-10-29 Oncotherapy Science, Inc. FOXM1 peptide and medicinal agent comprising the same
US8617562B2 (en) 2009-02-18 2013-12-31 Oncotherapy Science, Inc. FOXM1 peptides and immunogenic compositions containing them
WO2014010229A1 (en) * 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
WO2016021508A1 (ja) * 2014-08-04 2016-02-11 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
JP2019135494A (ja) * 2010-05-14 2019-08-15 ザ ジェネラル ホスピタル コーポレイション 腫瘍特異的なネオ抗原を同定する組成物および方法
WO2020027239A1 (ja) 2018-08-02 2020-02-06 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
US11452768B2 (en) 2013-12-20 2022-09-27 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US11834718B2 (en) 2013-11-25 2023-12-05 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status
US11939637B2 (en) 2014-12-19 2024-03-26 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009025117A1 (ja) 2007-08-20 2009-02-26 Oncotherapy Science, Inc. Cdca1ペプチド及びこれを含む薬剤
ES2952959T3 (es) 2015-03-27 2023-11-07 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra diversos tumores (SEQ ID N.º 25 - MXRA5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CN110191703B (zh) 2017-01-25 2022-04-08 奥塞免疫疗法公司 用于肽递送的稳定乳液的制造方法

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06317688A (ja) 1993-02-01 1994-11-15 General Electric Co <Ge> 複合核燃料容器およびそれの製造方法
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1999008521A1 (en) 1997-08-14 1999-02-25 Department Of The Army, U.S. Government Treatment or prophylaxis of retinal pathology and spinal cord injury
JPH11510507A (ja) 1995-08-03 1999-09-14 リュークスウニベルジテート トゥ ライデン 細胞由来の抗原提示小胞
JP2000512161A (ja) 1997-07-16 2000-09-19 アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル 「エキソソーム」と呼ばれる細胞内小胞、調製及び免疫刺激におけるこれらの使用
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2002094981A2 (en) * 2001-05-16 2002-11-28 Technion Research And Development Foundation Ltd. Method of identifying peptides capable of binding to mhc molecules, peptides identified thereby and their uses
WO2005089735A2 (en) * 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Compositions and methods for treating lung cancer
JP2006500949A (ja) * 2002-09-30 2006-01-12 オンコセラピー・サイエンス株式会社 非小細胞肺癌の診断のための方法
WO2007013480A2 (en) * 2005-07-29 2007-02-01 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053071A1 (en) 1997-05-23 1998-11-26 Biogen, Inc. Modulators of tissue regeneration
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
HUP0201757A3 (en) 1999-06-30 2010-01-28 Corixa Corp Compositoins and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) * 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) * 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) * 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1265582A2 (en) 1999-09-29 2002-12-18 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
CA2415544A1 (en) 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2003025010A2 (en) * 2001-09-17 2003-03-27 Eirx Therapeutics Limited Human delta-n p73 molecules and uses thereof
AU2003250831A1 (en) 2002-06-12 2003-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
US7514084B2 (en) 2002-09-12 2009-04-07 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
EP1546410A2 (en) 2002-09-30 2005-06-29 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
AU2003303305A1 (en) 2002-10-02 2004-09-30 Nuvelo,Inc. Novel nucleic acids and polypeptides
AU2003300680A1 (en) 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US7635673B2 (en) * 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
CN1898563B (zh) * 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 诊断乳腺癌的方法
EP1856278A2 (en) * 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
CN101273144B (zh) * 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
CN101283106A (zh) * 2005-07-27 2008-10-08 肿瘤疗法科学股份有限公司 小细胞肺癌的诊断方法
US7776341B2 (en) * 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
WO2009025117A1 (ja) 2007-08-20 2009-02-26 Oncotherapy Science, Inc. Cdca1ペプチド及びこれを含む薬剤
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
US20120171213A1 (en) 2009-09-10 2012-07-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
JPH06317688A (ja) 1993-02-01 1994-11-15 General Electric Co <Ge> 複合核燃料容器およびそれの製造方法
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH11510507A (ja) 1995-08-03 1999-09-14 リュークスウニベルジテート トゥ ライデン 細胞由来の抗原提示小胞
JP2000512161A (ja) 1997-07-16 2000-09-19 アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル 「エキソソーム」と呼ばれる細胞内小胞、調製及び免疫刺激におけるこれらの使用
WO1999008521A1 (en) 1997-08-14 1999-02-25 Department Of The Army, U.S. Government Treatment or prophylaxis of retinal pathology and spinal cord injury
WO2002094981A2 (en) * 2001-05-16 2002-11-28 Technion Research And Development Foundation Ltd. Method of identifying peptides capable of binding to mhc molecules, peptides identified thereby and their uses
JP2006500949A (ja) * 2002-09-30 2006-01-12 オンコセラピー・サイエンス株式会社 非小細胞肺癌の診断のための方法
WO2005089735A2 (en) * 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Compositions and methods for treating lung cancer
WO2007013480A2 (en) * 2005-07-29 2007-02-01 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸

Non-Patent Citations (61)

* Cited by examiner, † Cited by third party
Title
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS, article "Molecular Cloning"
"Molecular Cloning: A laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY, COLD SPRING HARBOR
"Strategies for Protein Purification and Characterization: A Laboratory Course Manual"
BENMOHAMED L ET AL., HUM. IMMUNOL., vol. 61, no. 8, 2000, pages 764 - 79
BETTER; HORWITZ, METHODS ENZYMOL, vol. 178, 1989, pages 476 - 96
BIRD; WALKER, TRENDS BIOTECH, vol. 9, 1991, pages 132 - 7
BOCZKOWSKI D ET AL., J EXP. MED., vol. 184, 1996, pages 465 - 72
BUTTERFIELD LH ET AL., J. IMMUNOL., vol. 161, 1998, pages 5607 - 13
CO ET AL., J IMMUNOL, vol. 152, 1994, pages 2968 - 76
DALBADIE-MCFARLAND G, PROC NATL ACAD SCI USA, vol. 79, 1982, pages 6409 - 13
DELUCA J.G.; MOREE, B.; HICKEY, J.M.; KILMARTIN, J.V.; SALMON, E.D.: "hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells", J. CELL BIOL., vol. 159, 2002, pages 549 - 555, XP002335933, DOI: doi:10.1083/jcb.200208159
DELUCA JG ET AL., CURR. BIOL., vol. 13, 2003, pages 2103 - 9
DELUCA JG, J. CELL BIOL., vol. 159, 2002, pages 549 - 55
DELUCA JQ ET AL., J. CELL BIOL., vol. 159, 2002, pages 549 - 55
DELUCA, J.G.; DONG, Y.; HERGERT, P; STRAUSS, J.; HICKEY, J.M.; SALMON, E.D.; MCEWEN, B.F.: "Hecl and Nuf2 Are Core Components of the Kinetochore Outer Plate Essential for Organizing Microtubule Attachment Sites.", MOL. BIOL. CELL, vol. 16, 2005, pages 519 - 531
DELUCA, J.G.; HOWELL, B.J.; CANMAN, J.C.; HICKEY, J.M.; FANG, G.; SALMON, E.D. ET AL.: "Nuf2 and Heel Are Required for Retention of the Checkpoint Proteins Madl and Mad2 to Kinetochores.", CURRENT BIOLOGY, vol. 13, 2003, pages 2103 - 2109
DERES K. ET AL., NATURE, vol. 342, 1989, pages 561 - 4
FALKENBURG JH ET AL., BLOOD, vol. 94, 1999, pages 1201 - 8
G. KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
HAYAMA S ET AL., CANCER RES, vol. 66, 2006, pages 10339 - 48
HAYAMA, S.; DAIGO, Y.; KATO, T.; ISHIKAWA, N.; YAMABUKI, T.; MIYAMOTO, M.; ITO, T.; TSUCHIYA, E.; KONDO, S.; NAKAMURA, Y: "Activation of CDCAI-KNTC2, Members of Centromere Protein Complex, Involved in Pulmonary Carcinogenesis.", CANCER RES., vol. 66, 2006, pages 10339 - 10348, XP002410940, DOI: doi:10.1158/0008-5472.CAN-06-2137
HIPP JD ET AL., IN VIVO, vol. 14, 2000, pages 571 - 85
HOOGENBOOM; WINTER, J MOL BIOL, vol. 227, 1992, pages 381 - 8
HUSTON ET AL., PROC NATL ACAD SCI USA, vol. 85, 1998, pages 5879 - 83
J. IMMUNOL., vol. 148, 1992, pages 1438
JOHNSON AG., CLIN. MICROBIOL. REV., vol. 7, 1994, pages 277 - 89
KAWAKAMI ET AL., J. IMMUNOL., vol. 142, 1989, pages 3452 - 3461
KOMORI H ET AL., CLIN. CANCER RES., vol. 12, 2006, pages 2689 - 97
KOMORI H, CLIN. CANCER RES., vol. 12, 2006, pages 2689 - 2697
KOMORI H, CLINICAL CANCER RESEARCH, vol. 12, 2006, pages 2689 - 2697
KONDO A, J. IMMUNOL., vol. 155, 1995, pages 4307 - 12
KUBO RT ET AL., J. IMMUNOL., vol. 152, 1994, pages 3913 - 24
KUGLER A, NAT MED, vol. 6, 2000, pages 332 - 6
LAMOYI, METHODS ENZYMOL, vol. 121, 1986, pages 652 - 63
LIU D ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 21415 - 24
LIU, D.; DING, D.; DU, J.; CAI, XIN.; HUANG, Y.; WARD, T.; SHAW, A.; YANG, Y.; HU, R.; JIN, C.: "Human NUF2 Interacts with Centromere-associated Protein E and Is Essential for a Stable Spindle Microtubule-Kinetochore Attachment", J.BIOL.CHEM., vol. 282, 2007, pages 21415 - 21424, XP002602449, DOI: doi:10.1074/JBC.M609026200
LIU, S.T.; RATTNER, J.B.; JABLONSKI, S.A.; YEN, T.J.: "Mapping the assembly pathways that specify formation of the trilaminar kinetochore plates in human cells.", J.CELLBIOL., vol. 175, 2006, pages 41 - 53
MAKITA M ET AL., CLIN. CANCER RES., vol. 8, 2002, pages 2626 - 31
MARK DF ET AL., PROC NATL ACAD SCI USA, vol. 81, 1984, pages 5662 - 6
MIYOSHI H ET AL., J. VIROL., vol. 72, 1998, pages 8150 - 8157
MORGAN ET AL., J. IMMUNOL., vol. 171, 2003, pages 3288
NAKAHARA S ET AL., CANCER RES., vol. 63, 2003, pages 4112 - 8
NATURE, vol. 344, 1990, pages 873
PLUCKTHUN; SKERRA, METHODS EMZYMOL, vol. 178, 1989, pages 497 - 515
RAMMENSEE HQ ET AL., IMMUNOGENETICS, vol. 41, 1995, pages 178 - 228
REEVES ME ET AL., CANCER RES., vol. 56, 1996, pages 5672 - 7
ROSENBERG SA ET AL., NAT MED, vol. 4, 1998, pages 321 - 7
ROUSSEAUX ET AL., METHODS ENZYMOL, vol. 121, 1986, pages 663 - 9
See also references of EP2186889A4
SHATA MT ET AL., MOL. MED. TODAY, vol. 6, 2000, pages 66 - 71
SHEDLOCK DJ; WEINER DB. ET AL., J. LEUKOC. BIOL., vol. 68, 2000, pages 793 - 806
STOVER CK, NATURE, vol. 31, 1991, pages 456 - 60
SUDA T ET AL., CANCER SCI., 2007
SUDA T, CANCER SCI., vol. 98, 2007, pages 1803 - 8
TAHARA-HANAOKA S ET AL., EXP. HEMATOL., vol. 30, 2002, pages 11 - 17
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 6
WIGGE PA. ET AL.: "The Ndc80p complex from Saccharomyces cerevisiae contains conserved centromere components and has a function in chromosome segregation", J.CELL BIOL., vol. 152, no. 2, 2001, pages 349 - 360, XP002263372 *
YOKOMINE K ET AL., CANCER SCI., vol. 98, 2007, pages 1930 - 5
YOSHITAKE Y ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 6437 - 48
ZOLLER MJ; SMITH M, NUCLEIC ACIDS RES, vol. 10, 1982, pages 6487 - 500

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943295B2 (en) 2005-07-29 2011-05-17 Oncotherapy Science, Inc. Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex
US8569244B2 (en) 2007-08-20 2013-10-29 Oncotherapy Science, Inc. FOXM1 peptide and medicinal agent comprising the same
US9073968B2 (en) 2007-08-20 2015-07-07 Oncotherapy Science, Inc. FOXM1 peptide and medicinal agent comprising the same
US9415096B2 (en) 2007-08-20 2016-08-16 OncoTherapy Sciences, Inc. FOXM1 peptide and medicinal agent comprising the same
US9387238B2 (en) 2008-06-19 2016-07-12 Oncotherapy Science, Inc. CDCA1 epitope peptides and vaccines containing the same
WO2009153992A1 (en) * 2008-06-19 2009-12-23 Oncotherapy Science, Inc. Cdca1 epitope peptides and vaccines containing the same
US10711047B2 (en) 2008-06-19 2020-07-14 Oncotherapy Science, Inc. CDCA1 epitope peptides and vaccines containing the same
US8617562B2 (en) 2009-02-18 2013-12-31 Oncotherapy Science, Inc. FOXM1 peptides and immunogenic compositions containing them
JP7008049B2 (ja) 2010-05-14 2022-02-10 ザ ジェネラル ホスピタル コーポレイション 腫瘍特異的なネオ抗原を同定する組成物および方法
JP2019135494A (ja) * 2010-05-14 2019-08-15 ザ ジェネラル ホスピタル コーポレイション 腫瘍特異的なネオ抗原を同定する組成物および方法
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
WO2014010229A1 (en) * 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
JP2015529629A (ja) * 2012-07-10 2015-10-08 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン
US9687538B2 (en) 2012-07-10 2017-06-27 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same
US10206989B2 (en) 2012-07-10 2019-02-19 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same
US20150190490A1 (en) * 2012-07-10 2015-07-09 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
US11834718B2 (en) 2013-11-25 2023-12-05 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US11452768B2 (en) 2013-12-20 2022-09-27 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
JP7266318B2 (ja) 2014-08-04 2023-04-28 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
EP4282883A2 (en) 2014-08-04 2023-11-29 OncoTherapy Science, Inc. Cdca1-derived peptide and vaccine containing same
KR20170040315A (ko) 2014-08-04 2017-04-12 온코세라피 사이언스 가부시키가이샤 Cdca1-유래 펩티드 및 이를 포함하는 백신
JPWO2016021508A1 (ja) * 2014-08-04 2017-05-18 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
US10676514B2 (en) 2014-08-04 2020-06-09 Oncotherapy Science, Inc. CDCA1-derived peptide and vaccine containing same
JP2020062031A (ja) * 2014-08-04 2020-04-23 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
JP2022050382A (ja) * 2014-08-04 2022-03-30 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
JP6999185B2 (ja) 2014-08-04 2022-02-04 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
WO2016021508A1 (ja) * 2014-08-04 2016-02-11 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
RU2699543C2 (ru) * 2014-08-04 2019-09-06 Онкотерапи Сайенс, Инк. Пептид, полученный из cdca1, и содержащая его вакцина
US11939637B2 (en) 2014-12-19 2024-03-26 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2020027239A1 (ja) 2018-08-02 2020-02-06 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
KR20210040106A (ko) 2018-08-02 2021-04-12 온코세라피 사이언스 가부시키가이샤 Cdca1유래 펩타이드 및 이를 포함하는 백신
US12195559B2 (en) 2018-08-02 2025-01-14 Oncotherapy Science, Inc. CDCA1-derived peptide and vaccine containing same

Also Published As

Publication number Publication date
CN101835892B (zh) 2013-11-06
BRPI0815578A2 (pt) 2015-02-18
MX2010002001A (es) 2010-03-11
EP2186889A4 (en) 2010-11-10
US8598125B2 (en) 2013-12-03
IL203898A0 (en) 2011-07-31
CN101835892A (zh) 2010-09-15
TW200916114A (en) 2009-04-16
EP2186889B1 (en) 2015-04-01
AU2008290061B2 (en) 2014-01-30
RU2013112616A (ru) 2014-09-27
SG183698A1 (en) 2012-09-27
EP2186889A1 (en) 2010-05-19
US20110152199A1 (en) 2011-06-23
TWI523660B (zh) 2016-03-01
RU2010110564A (ru) 2011-09-27
RU2486195C2 (ru) 2013-06-27
CA2696701A1 (en) 2009-02-26
JP5493076B2 (ja) 2014-05-14
AU2008290061A1 (en) 2009-02-26
PT2186889E (pt) 2015-06-17
IL203898A (en) 2013-11-28
KR20100063060A (ko) 2010-06-10
CA2696701C (en) 2017-01-24
BRPI0815578B8 (pt) 2023-01-03
PL2186889T3 (pl) 2015-09-30
DK2186889T3 (en) 2015-06-08
JPWO2009025117A1 (ja) 2010-11-18
HK1141312A1 (en) 2010-11-05
BRPI0815578B1 (pt) 2020-04-07
KR101610353B1 (ko) 2016-04-07
ES2537323T3 (es) 2015-06-05

Similar Documents

Publication Publication Date Title
WO2009025117A1 (ja) Cdca1ペプチド及びこれを含む薬剤
WO2009025116A1 (ja) Cdh3ペプチド及びこれを含む薬剤
RS50966B (sr) Agonisti pyy i njihova upotreba
MX2011011960A (es) Peptidos penetradores de celulas.
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
WO2005030797A3 (en) Melanocortin receptor agonists
WO2003083118A1 (fr) Genes codant l&#39;acetolactase synthase
EP2476698A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
WO2009025196A1 (ja) Foxm1ペプチドおよびこれを含む薬剤
NZ600731A (en) Oxyntomodulin peptide analogue
WO2007091030A3 (en) Peptide sequences and compositions
WO2006066258A3 (en) Lipoconjugation of peptides
EP2386567A3 (en) Mutants of cholesterol-dependent cytolysins and uses thereof
MX2010004371A (es) Proteasa de streptomyces.
WO2007048857A8 (es) USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE
WO2008113536A8 (en) Neurotrophic peptides
EP2481748A3 (en) Foxp3 peptide vaccine
WO2010057242A3 (de) Vakzin
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
MX2010005816A (es) Epítopos de péptido de stat3.
NZ589365A (en) Peptidyl diacylglycerides
WO2007058267A8 (ja) 新規タンパク質及びそれをコードする遺伝子
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2005068632A8 (ja) ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880112396.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777198

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009528970

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 203898

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2696701

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/002001

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008290061

Country of ref document: AU

Ref document number: 2008777198

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107005388

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1487/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010110564

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2008290061

Country of ref document: AU

Date of ref document: 20080613

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12673434

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0815578

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100219